FDA Grants Emergency Use Authorization for Gaithersburg Based Novavax’s COVID-19 Booster

“The U.S. now has access to the Novavax COVID-19 Vaccine, Adjuvanted, the first protein-based option, as a booster,” said Stanley C. Erck, President and Chief Executive Officer, Novavax. “According to CDC data, almost 50 percent of adults who received their primary series have yet to receive their first booster dose. Offering another vaccine choice may help increase COVID-19 booster vaccination rates for these adults.”

The FDA EUA decision was based on data from the Phase 3 Prevent-19 clinical trial and from the U.K.-sponsored COV-BOOST trial. In the Phase 3 trial, a single booster dose of the Novavax COVID-19 Vaccine, Adjuvanted was administered to healthy adult participants aged 18 and older approximately eight or 11 months after their primary series. Following a booster dose, antibody levels increased significantly relative to pre-boost levels, rising above levels associated with protection in the Phase 3 trials. Neutralizing antibodies also increased by 34- to 27-fold compared to pre-boost levels when boosted at eight or 11 months. In the COV-BOOST trial, the Novavax COVID-19 Vaccine, Adjuvanted increased antibody titers when used as a third dose following initial dosing with another authorized COVID-19 vaccine (heterologous boosting).

In the trial, following the booster, local and systemic reactions had a median duration of approximately two days. The incidence of Grade 3 or higher events remained relatively low. Safety reporting of reactogenicity events showed an increasing incidence across all three doses of the Novavax COVID-19 Vaccine, Adjuvanted, often seen with increased immunogenicity. Among participants 18 years of age and older, solicited adverse reactions following administration of a booster dose of the Novavax COVID-19 Vaccine, Adjuvanted were injection site pain/tenderness (81.1%), fatigue/malaise (63.4%), muscle pain (63.0%), headache (52.9%), joint pain (30.3%), nausea/vomiting (14.7%), injection site swelling (8.4%), injection site redness (6.3%), and fever (6.3%).

The next step for the vaccine is a policy recommendation for use as a first booster from the Centers for Disease Control and Prevention (CDC). Doses of the Novavax COVID-19 Vaccine, Adjuvanted are available for use in the U.S. pending this final step and can be located on Vaccines.gov.

Novavax’ vaccine is also available for use as a booster in adults aged 18 and older in the European UnionJapanAustraliaNew ZealandSwitzerland, and Israel. In addition, a number of countries have policy recommendations allowing use of the vaccine as a heterologous or homologous booster dose. In the U.S., the FDA granted EUA for a two-dose primary series in adults aged 18 and older in July and for adolescents aged 12 through 17 in August. Following these EUA’s, the CDC recommended the vaccine for use as a primary series for both age groups.

This project has been supported in part with federal funds from the Department of Health and Human Services (HHS); the Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority (BARDA), through the Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND) under Contract Number W15QKN-16-9-1002, Project Number MCDC2011-001.

Use of the Novavax COVID-19 Vaccine, Adjuvanted in the U.S.
The Novavax COVID-19 Vaccine, Adjuvanted vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19) as a primary series individuals 12 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted vaccine is also authorized to provide a first booster dose at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

The emergency use of this product is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.

Authorized Use
The Novavax COVID-19 Vaccine, Adjuvanted is authorized for use under an Emergency Use Authorization (EUA) to provide a two-dose primary series for active immunization to prevent coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 years of age and older. The Novavax COVID-19 Vaccine, Adjuvanted vaccine is also authorized to provide a first booster dose at least 6 months after completion of primary vaccination with an authorized or approved COVID-19 vaccine to individuals 18 years of age and older for whom an FDA-authorized mRNA bivalent COVID-19 booster vaccine is not accessible or clinically appropriate, and to individuals 18 years of age and older who elect to receive the Novavax COVID-19 Vaccine, Adjuvanted because they would otherwise not receive a booster dose of a COVID-19 vaccine.

IMPORTANT SAFETY INFORMATION

Contraindications
Do not administer the Novavax COVID-19 Vaccine, Adjuvanted to individuals with a known history of a severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted.

Warnings and Precautions
Management of Acute Allergic Reactions: Appropriate medical treatment to manage immediate allergic reactions must be immediately available in the event an acute anaphylactic reaction occurs following administration of the Novavax COVID-19 Vaccine, Adjuvanted. Monitor the Novavax COVID-19 Vaccine, Adjuvanted recipients for the occurrence of immediate adverse reactions according to the Centers for Disease Control (CDC) and Prevention guidelines.
Myocarditis and Pericarditis: Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of the Novavax COVID-19 Vaccine, Adjuvanted (see Full EUA Prescribing Information). The CDC has published considerations related to myocarditis and pericarditis after vaccination, including for vaccination of individuals with a history of myocarditis or pericarditis (https://www.cdc.gov/vaccines/covid-19/clinical-considerations/interim-considerations-us.html#myocarditis-pericarditis).
Syncope (fainting): May occur in association with administration of injectable vaccines. Procedures should be in place to avoid injury from fainting.
Altered Immunocompetence: Immunocompromised persons, including individuals receiving immunosuppressant therapy, may have a diminished immune response to the Novavax COVID-19 Vaccine, Adjuvanted.
Limitations of Vaccine Effectiveness: The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.

Adverse Reactions
Adverse reactions reported in clinical trials following administration of the Novavax COVID-19 Vaccine, Adjuvanted include injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling, fever, chills, injection site pruritus, hypersensitivity reactions, lymphadenopathy-related reactions, myocarditis, and pericarditis.

Myocarditis, pericarditis, anaphylaxis, paresthesia, and hypoesthesia have been reported following administration of the Novavax COVID-19 Vaccine, Adjuvanted outside of clinical trials.

Additional adverse reactions, some of which may be serious, may become apparent with more widespread use of the Novavax COVID-19 Vaccine, Adjuvanted.

Reporting Adverse Events and Vaccine Administration Errors
The vaccination provider enrolled in the federal COVID-19 Vaccination Program is responsible for mandatory reporting of the following to the Vaccine Adverse Event Reporting System (VAERS):

  • vaccine administration errors whether or not associated with an adverse event,
  • serious adverse events (irrespective of attribution to vaccination),
  • cases of myocarditis,
  • cases of pericarditis,
  • cases of Multisystem Inflammatory Syndrome (MIS), in adults and children, and
  • cases of COVID-19 that results in hospitalization or death.

Complete and submit reports to VAERS online: For further assistance with reporting to VAERS, call 1-800-822-7967. The reports should include the words “Novavax COVID-19 Vaccine, Adjuvanted EUA” in the description section of the report.

To the extent feasible, report adverse events to Novavax, Inc. using the following contact information or by providing a copy of the VAERS form to Novavax, Inc. Website: www.NovavaxMedInfo.com, Fax Number: 1-888-988-8809, Telephone Number: 1-844-NOVAVAX (1-844-668-2829).

Please click to see the Novavax COVID-19 Vaccine, Adjuvanted Fact Sheet for Healthcare Providers Administering Vaccine (Vaccination Providers) and EUA Full Prescribing Information.

Recent Stories

The MD Department of Environment has issued a CODE ORANGE Air Quality Alert Saturday, May 25 for parts of the area- particularly from the eastern DC suburbs through Baltimore and…

On May 2nd, the Montgomery County Animal Services & Adoption Center (MCASAC) announced it was closed to the public due to an outbreak of Canine Influenza (CIV). On Friday, May…

“Prioritizing Safety Helps You Arrive Safely, Follow Suggested Bay Bridge Drive Times to Reduce Delays, Know Your All-Electronic Tolling Payment Options”

By Ben Shlesinger With the Department of Justice suing Ticketmaster’s parent company, Live Nation, for “monopolizing markets across the live concert industry,” I wanted to take a look back at…

Washington City Paper is hosting its annual Best of D.C. contest -- and Well-Paid Maids is eyeing the Best Maid Service category. If you missed it: Well-Paid Maids has secured first place for the past three years. Can you help us snag gold again? Simply go to the ballot and write in your vote for the best maid service. In case you need a refresher before you vote, Well-Paid Maids is the only certified living-wage cleaning company in the D.C. area. We pay our cleaners, who are W-2 employees, at least $24 an hour and offer benefits like insurance, 24 paid days off per year and more. Voting is open until June 10 at 5 p.m., and the winner will be announced July 18. (We'll keep you posted!) Thank you for your support -- and if you still haven't booked a spring cleaning yet, now is the time!

Submit your own Announcement here.

Oak Chapel is excited that Priority Partners Managed Care Organization (PPMCO) in partnership with Johns Hopkins HealthCare (JHHC) have selected the Oak Chapel Hub as the location for the first mini-food pantry/mini library in Montgomery County. Please join us for the cupboard unveiling on Saturday, May 18th, at 10 AM (rain or shine). This is scheduled to be an outdoor event. If there is inclement weather, the event will be held in the multi-purpose room of the main church building (Hub distribution location). The cupboard will be fully stocked and ready for the community to take what they need and leave what they can. It is a privilege to be able to continue to serve the 20906 community.

Fighting food insecurity, feeding families.

Submit your own Announcement here.

Movie being filmed in McLean, VA, needs your support

A local community movie is filming in our area in June and needs contributions!

Local actors, teens, teachers, housewives, and retired residences are trying to make this film happen but we need your help.

This is an educational short story about teens learning how to navigate when they don't feel accepted by their friends and what to do to find acceptance. Yet this film isn't just for teens. In your life have you ever felt like you weren't accepted??

Come be a part of the audience for this film! Invite your friends. Be a part of this film being produced right here in our area.

This is a social impact film that will show locally and internationally at film festivals in 2025 and also at colleges.

More information can be found here. DONATE TODAY:

https://www.filmindependent.org/sponsored-projects/ultimate-bias/

https://www.silvanomarifilms.com/jis

This is a not-for-profit film and donations are tax-deductible.

Free Community Father-Daughter Dance

Fathers and father figures, create unforgettable memories with your daughter at our free community father-daughter dance on June 1st, from 6-8 pm. Hosted outdoors at Olney Baptist Church. This event offers a delightful outdoor experience complete with a DJ spinning tunes, interactive games, a charming photo booth, delicious treats, and exciting raffle prizes. Fathers/father figures and daughters of all ages are warmly welcomed to share in this special evening together. Join us for an evening of joy, laughter, and cherished moments!

In the spirit of giving back to our community, we are partnering with Quest to Feed Montgomery to make a meaningful difference in the lives of those in need. We kindly ask each attendee to bring along a non-perishable food item to donate during the event. Every contribution, no matter how small, will go a long way in supporting families facing food insecurity in our area.

×

Subscribe to our mailing list